Efficacy of RestoreX after prostatectomy: open-label phase of a randomized controlled trial.
Andrew Zganjar, Amir Toussi, Matthew Ziegelmann...
https://pubmed.ncbi.nlm.nih.gov/37088866/Actively Recruiting
Led by Charitable Union for the Research and Education of Peyronie's Disease · Updated on 2026-08-26
200
Participants Needed
4
Research Sites
104 weeks
Total Duration
Researchers are evaluating the RestoreX penile traction device to see if it helps preserve erectile function in men undergoing robotic-assisted prostatectomy with bilateral nerve preservation and moderate or better baseline erectile function. This study aims to confirm previous findings that RestoreX may improve erectile function and penile length after prostatectomy, conditions that often lead to sexual dysfunction and other complications. The trial is a large, multi-center, randomized controlled study with a prevention focus. Participants in the treatment group will use the RestoreX device for 30 to 60 minutes daily, 5 to 7 days per week, starting one month after prostatectomy and continuing for five months. After six months, all participants may choose to use the device for an additional three months during an open-label phase. The device provides direct traction to the penis and is classified as a class I orthotic device, previously studied for safety and efficacy in improving erectile function and penile length. Throughout the study, participants will be assessed using the International Index of Erectile Function at 3, 6, and 9 months, with the primary outcome measured at 6 months. Researchers will monitor changes in erectile function and other questionnaire outcomes, as well as any adverse events. The study is scheduled for three years to allow sufficient enrollment and follow-up, with participant involvement spanning the treatment and open-label phases.
CONDITIONS
Efficacy of RestoreX Penile Traction Therapy In Preserving Erectile Function Post-Prostatectomy
L
Landon Trost, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Charitable Union for the Research and Education of Peyronie's Disease
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | RestoreX penile traction therapy | No therapy control | Vacuum erection device (VED) |
|---|---|---|---|
| What it is | A device-based penile traction therapy applied daily starting 1 month post‑prostatectomy for 5 months (followed by open‑label continued use) | Participants receive no penile rehabilitation therapy during the randomized 1–6 month period | A non‑invasive device that applies suction to promote penile blood flow and help preserve penile tissue after prostatectomy |
| Role in trial | Investigational treatment arm | Control arm with no therapy | External comparator representing a common post‑prostatectomy care option |
| Primary use | Prevention of penile length loss and preservation of erectile function post‑prostatectomy | Observation without intervention; serves as comparator for spontaneous recovery | Frequently used to maintain penile length and support erectile recovery |
| How it is performed | Device worn 30–60 minutes per day, 5–7 days per week starting 1 month after surgery | No intervention applied during randomized period | User applies vacuum using a handheld device daily, typically for 10–15 minutes per session |
| Evidence status | RCT evidence shows preservation of penile length (+1.6 cm vs +0.3 cm) and erectile function (IIEF‑EF ≈ 0 vs −6.5 decline) at 6 months | Spontaneous decline in erectile function and minimal length preservation observed | VEDs help preserve penile tissue and support recovery, though evidence for erectile function improvement is mixed |
| Important risks | Transient mild discomfort or skin irritation reported; generally well tolerated | Not applicable (no treatment administered) | Generally safe but may cause temporary bruising or discomfort |
| Important limitations | Single‑center study with modest sample size; results need external validation | Not a standard of care comparator; may overstate relative effect size | Lack of large randomized trials validating erectile function benefit post‑prostatectomy |
| Patient impact | Participants using RestoreX maintained erectile scores and penile length, potentially enhancing sexual satisfaction | Decline in function and length may negatively affect post‑operative sexual quality of life | May support patient wellbeing by helping preserve penile structure, though direct impact on sexual satisfaction is less certain |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 5 months
Participants in the treatment group use the RestoreX device for 30 to 60 minutes daily, 5 to 7 days per week, starting 1 month after prostatectomy until 6 months. Control group participants do not use the device during this time.
Regular visits during treatment period
Duration - 3 months
From 6 to 9 months post-prostatectomy, all participants may choose to use the RestoreX device if they wish. Only the direct traction function will be used during this phase.
Visits at 6 and 9 months for assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Andrew Zganjar, Amir Toussi, Matthew Ziegelmann...
https://pubmed.ncbi.nlm.nih.gov/37088866/Charitable Union for the Research and Education of Peyronie's Disease
Lead Sponsor